Ataxia-Telangiectasia (A-T) is a rare genetic disorder with an incidence of approximately three in one million births. Patients with A-T often end up in a wheelchair by the age of ten and have a life expectancy of 25 years. Approximately 40 children in Australia currently have A-T.

Research Objectives

Status

Current

Recruitment

Closed

Patient Group

Patients with Ataxia-Telangiectasia (AT)

Study location

Wesley Research Institute

Phase

2

Study type

Investigator Initiated

    Lead investigator    
            Prof David Coman        

        Clinical trial coordinator		
				Sarah Harriman			

Technical title

A Phase 2A/2B placebo-controlled randomised clinical trial to test the ability of triheptanoin to protect primary airway epithelial cells obtained from patients with ataxia-telangiectasia against death induced by glucose deprivation.

About this research project

This genetic disorder leads to ataxia; the inability to walk, talk and use fine motor skills because of the neurological impairment. A-T patients also suffer from cystic-fibrosis-like lung disease due to immunodeficiency as well as cancer accounting for a high death rate.

The symptoms of A-T are described as the ‘worst parts’ of cerebral palsy, cystic fibrosis and muscular dystrophy with a high risk of cancer and lung disease. There is unfortunately no effective therapy for this illness.

This study will investigate the use of Triheptanoin, a dietary fat supplement which has the potential to boost energy metabolism and significantly improve neurological symptoms. This trial has given families of patients the hope that they are able to have their children for longer by slowing down the progression of the disease.

Latest News

Queensland claims world-first Chair in Spatial Medicine

In a landmark move in diagnosing and treating chronic disease, Queensland has unveiled the world’s first Chair in Spatial Medicine – a prestigious, philanthropically-funded research leadership position appointed to Associate Professor Arutha Kulasinghe.

Gluten Threshold Study Findings

WRI researchers have made a groundbreaking discovery showing that even extremely small amounts of gluten can trigger measurable immune activation in people with treated coeliac disease – findings that could help refine international food labelling standards.

How Kira is Helping to Shape Global Coeliac Research

When Kira was invited to participate in the Gluten Threshold Study, led by Coeliac Disease & Immune Health Research Program Clinical Director Dr James Daveson, Kira didn’t hesitate. The study’s findings are expected to influence international food labelling standards – an outcome that gives Kira a genuine sense of purpose.

1 2 3 … 34 Next »

Rare Diseases

Ataxia-Telangiectasia (AT) Study